FDA Approves FOUNDAYO (ORFORGLIPRON) — New Treatment Available

WHY IT MATTERS

Without information about which rare disease FOUNDAYO treats, we cannot specify the patient impact — the article lacks details about the condition it addresses or which patients are eligible.

The FDA has approved a new drug called FOUNDAYO (orforglipron), made by Eli Lilly. This approval means the medication is now available for patients to use. The drug was officially approved on April 1, 2026.

Drug: FOUNDAYO Generic name: ORFORGLIPRON Sponsor: ELI LILLY AND CO Application: NDA220934 (ORIG) FDA approval date: 2026-04-01 Source: FDA Drugs@FDA database

ASK YOUR DOCTOR

Ask your doctor whether FOUNDAYO might be appropriate for your condition and whether you meet the eligibility criteria for this newly approved treatment.